Coherus OncologyFRA:8C5 -4.22%45 Current Ratio is 1.54 as of Mar. 2026, which is 45% below its 10-year median of 2.81. GuruFocus rates FRA:8C5 with a GF Score™ of 45/100 and a GF Value™ of €0.65 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,412 Biotechnology companies, Coherus Oncology ranks worse than 75.21% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Coherus Oncology's current ratio for the quarter that ended in Mar. 2026 was 1.54.
Coherus Oncology has a current ratio of 1.54. It generally indicates good short-term financial strength.
The historical rank and industry rank for Coherus Oncology's Current Ratio or its related term are showing as below:
FRA:8C5'
s Current Ratio Range Over the Past 10 Years
Min: 1.17 Med: 2.81 Max: 7.78
Current: 1.54
During the past 13 years, Coherus Oncology's highest Current Ratio was 7.78. The lowest was 1.17. And the median was 2.81.
FRA:8C5's Current Ratio is ranked worse than 75.21% of 1412
companies
in the Biotechnology industry
Industry Median: 3.9
vs FRA:8C5: 1.54
Coherus Oncology (FRA:8C5) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Coherus Oncology Current Ratio Related Terms
Coherus Oncology Current Ratio Historical Data
* Premium members only.
The historical data trend for Coherus Oncology's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:8C5 vs TARA, KPTI, CNTN: Current Ratio Comparison
For the Biotechnology subindustry, Coherus Oncology's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus Oncology Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus Oncology's Current Ratio distribution charts can be found below:
* The bar in red indicates where Coherus Oncology's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus Oncology (FRA:8C5) has a Current Ratio of 1.54 as of Mar. 2026. This is 45% below median its historical median of 2.81. Over the past decade, Coherus Oncology's Current Ratio has ranged from 1.17 to 7.78. According to the industry distribution chart, Coherus Oncology ranks #1062 out of 1412 companies in the Biotechnology industry, placing it in the top 75.2%.
Is Coherus Oncology's Current Ratio too high?
Coherus Oncology's current Current Ratio of 1.54 is 45% below median its 10-year median of 2.81. Over the past 10 years, this metric has ranged from a low of 1.17 to a high of 7.78. The Biotechnology industry median Current Ratio is 3.90. Coherus Oncology's value of 1.54 is 60.5% below this industry median. Based on the distribution chart, Coherus Oncology ranks #1062 out of 1412 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Coherus Oncology has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Coherus Oncology's Current Ratio compare to TARA and KPTI?
According to the Biotechnology industry distribution chart, Coherus Oncology ranks #1062 out of 1412 companies for Current Ratio. This places Coherus Oncology in the lower half of its industry. The industry median Current Ratio is 3.90. Coherus Oncology's value of 1.54 is 60.5% below this benchmark. Historically, Coherus Oncology's own Current Ratio has ranged from 1.17 to 7.78 over the past decade. While the company's 10-year median is 2.81 vs. the industry median of 3.90, Coherus Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.90, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Coherus Oncology's current Current Ratio of 1.54 is 60.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coherus Oncology's current Current Ratio is 1.54, which is 45% below median its own 10-year median of 2.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coherus Oncology stock overvalued right now?
Based on GuruFocus' analysis, Coherus Oncology (FRA:8C5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.65, compared to a current price of €1.20 — trading 85.2% above its estimated fair value. The current Current Ratio is 1.54, which is 45% below median its 10-year median of 2.81 and 60.5% below the Biotechnology industry median of 3.90. Coherus Oncology's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Coherus Oncology (FRA:8C5), the current Current Ratio is 1.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coherus Oncology (FRA:8C5) Overvalued in 2026?
Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued.
The current stock price of €1.20 is trading 85.2% above its estimated GF Value™ of €0.65.
GuruFocus considers Coherus Oncology to be Significantly Overvalued.
Key valuation signals for FRA:8C5:
Current Ratio: 1.54 (45% below median its 10-year median of 2.81)
GF Value™: €0.65 vs. price of €1.20 (85.2% above fair value)
Industry Position: 60.5% below the Biotechnology median (#1062 of 1412)
No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
45GF Score
Get the complete analysis for FRA:8C5
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8C5 has been successfully added to your 
